Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

Autor:	Ulrich Costabel, Carlo Albera, Marilyn K. Glassberg, Lisa H. Lancaster, Wim A. Wuyts, Ute Petzinger, Frank Gilberg, Klaus-Uwe Kirchgaessler, Paul W. Noble
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Advanced disease Antifibrotic Idiopathic pulmonary fibrosis Lung function Pirfenidone Diseases of the respiratory system RC705-779
Zdroj:	Respiratory Research, Vol 20, Iss 1, Pp 1-4 (2019)
Druh dokumentu:	article
ISSN:	1465-993X
DOI:	10.1186/s12931-019-1021-2
Popis:	Abstract Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/7d687304dbbb497eba5dcba3618502f1 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.